Symbols

QUCY

Mainz Biomed·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About QUCY

Mainz Biomed N.V.

A molecular genetics cancer diagnostics company

Industry

Biological Technology

Established Date

03/08/2021

Listing Date

11/05/2021

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

mainzbiomed.com

Security Type

Common stock

Office address

Robert Koch Strasse 50, 55129 Mainz, Germany

Business

Introduction

Mainz Biomed N.V. was incorporated in the Netherlands on March 8, 2021. The company is a molecular genetics cancer diagnostic company established in 2021 to acquire PharmGenomics GmbH with the aim of commercializing its product portfolio in Europe and the United States. The company focuses on the diagnostic side of the cancer industry. The company competes with other entities that develop and offer diagnostic tests to detect the presence of cancer. The company's core product is the CRC screening stool DNA test, and they are in the early stages of researching a similar test for pancreatic cancer.

Company Financials

EPS

QUCY has released its 2023 Q4 earnings. EPS was reported at -0.25, versus the expected -0.25, meeting expectations. The chart below visualizes how QUCY has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

QUCY has released its 2023 Q4 earnings report, with revenue of 214.76K, reflecting a YoY change of 11.11%, and net profit of -5.18M, showing a YoY change of 36.70%. The Sankey diagram below clearly presents QUCY's revenue sources and cost distribution.